Full Press Release Details
MINNEAPOLIS , Oct. 12, 2018 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China . Chuck Kummeth , President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice President, Shenzhen Association of Medical Devices, all attended the meeting and signing ceremony.
Yan Pingyi added, "Micropoint is excited about this collaboration because it will allow us to develop diagnostic tools for monitoring patients' responses to cancer immunotherapy and identifying potential adverse effects, such as the cytokine release syndrome. This agreement leverages our respective strengths. We understand the China diagnostic market and have developed the necessary regulatory infrastructure to serve it. Having access to Bio-Techne's key reagents and additional immunoassay testing platforms will help us succeed in this market."
About Bio-Techne Corporation (NASDAQ: TECH )
Contact: Dave Eansor , President, Protein Sciences Segment, 612-379-2956
SOURCE Bio-Techne Corporation